Polymedco Supports CRC Screening Programs in Safety Net Organizations - News and Weather For The Quad Cities -

Polymedco Supports CRC Screening Programs in Safety Net Organizations

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Polymedco Cancer Diagnostic Products, LLC

CORTLANDT MANOR, N.Y., June 9, 2014 /PRNewswire/ -- Polymedco Cancer Diagnostic Products, LLC ("Polymedco CDP") is pleased to announce a colorectal cancer (CRC) screening initiative supporting screening for CRC in the underserved, underinsured and newly insured persons in the US.  Polymedco CDP fecal immunochemical test (FIT) product line has been successfully utilized in multiple programs to screen for CRC, and now it is being subsidized by Polymedco CDP to establish organized screening programs in Safety Net Medical Centers.  Colorectal cancer is among the leading causes of cancer deaths, but nearly half of people who die failed to get screened.

Early detection and treatment dramatically increase chances of survival of CRC. Screening is the most realistic approach to reducing new cases.  The ability to pay for screening should not be a barrier to being screened for this preventable disease.

The OC automated FIT and manual OC Light® test are a quick easy and effective screening methods that measure human hemoglobin in the patient's stool.   The tests can be performed at home with little disruption to the patient's daily routine – requiring only one sample collection and no changes to diet or medication. The higher specificity of FIT means that there are less false positive results.

"Our goal is to introduce the benefits of getting an annual screening using a fecal immunochemical test (FIT) to all US residents served by our nation's Safety Net Medical Centers," said Drew Cervasio, President of Polymedco.   "It is time to pay attention to the advances that can drive more patients to find colorectal cancer earlier, and access to these tests should be available to all."

"Through these screening tests, we are better able to accurately identify at-risk patients and send more of the right patients for further evaluation and colonoscopy," said Pete Welsh, Executive Vice President and co-owner of Polymedco, PDC. "We are proud to initiate an effort that will ensure residents of our country will have access to the best options for their healthcare needs."

About Polymedco Cancer Diagnostic Products, LLC

Polymedco Cancer Diagnostic Products, LLC is a leading manufacturer, marketer, and distributer in the clinical laboratory marketplace. Polymedco supplies clinical diagnostic test kits and devices that are specialized in cancer. We are a world leader in non-invasive colorectal cancer screening technology, providing the new standard of care with the OC -Auto® product line. Since 1980, Polymedco has evolved into a highly skilled and successful marketing, sales, and manufacturing organization.

Combined with an experienced team of field representatives and strong technical service personnel, Polymedco Cancer Diagnostic Products provides a high level of customer, technical and reimbursement support. To reach Polymedco Inc. via the worldwide web, log on to www.polymedco.com.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

805 Brady Street, Davenport, IA 52803

Telephone: 563.383.7000
Fax: 563.383.7131
Email: news@kwqc.com

Can’t find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 Young Broadcasting of Davenport, Inc. A Media General Company.